Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. (Record no. 16181809)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01917 a2200493 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515021731.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200604s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1527-7755 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1200/JCO.2005.03.4900 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Janmaat, Maarten L |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20060413 |
| 245 00 - TITLE STATEMENT | |
| Title | Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Date of publication, distribution, etc. | Apr 2006 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1612-9 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Class I Phosphatidylinositol 3-Kinases |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | ErbB Receptors |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Esophageal Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Extracellular Signal-Regulated MAP Kinases |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gefitinib |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gene Dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Genes, ras |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phosphatidylinositol 3-Kinases |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phosphorylation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Proto-Oncogene Proteins c-akt |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Quinazolines |
| General subdivision | adverse effects |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gallegos-Ruiz, Mariëlle I |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rodriguez, José A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Meijer, Gerrit A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vervenne, Walter L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Richel, Dick J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Van Groeningen, Cees |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Giaccone, Giuseppe |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Related parts | vol. 24 |
| -- | no. 10 |
| -- | p. 1612-9 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1200/JCO.2005.03.4900">https://doi.org/10.1200/JCO.2005.03.4900</a> |
| Public note | Available from publisher's website |
No items available.